Research programme: anti cancer bispecific antibodies - Rondo Therapeutics
Alternative Names: Bispecific antibodies - Rondo TherapeuticsLatest Information Update: 06 Apr 2022
At a glance
- Originator Rondo Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours